



Express Mail Label No. EM015925413US

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/570,117
Sheet 1 of 3				Filing Date	February 28, 2006
				First Named Inventor	Joerg Heyer
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket No.	GEN/022

U.S. PATENT DOCUMENTS					
Examiner initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		4,736,866	04/12/88	Leder et al.	
		6,506,559	01/14/03	Fire et al.	
		6,639,121	10/28/03	DePinho et al.	
		2002/0086356	07/04/02	Tuschl et al.	

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 99/32619	07/01/99	The Carnegie Institute of Washington; The University of Massachusetts		
		WO 01/09308	02/08/01	Dana-Farber Cancer Institute		
		WO 01/36646	05/25/01	Cancer Research Campaign Technology Limited		
		WO 01/68836	09/20/01	Genetica, Inc.; Cold Spring Harbor Laboratory		

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Bao, R., <i>et al.</i> , "Activation of cancer-specific gene expression by the survivin promoter," <i>J. of the National Cancer Inst.</i> 94:522-528 (2002).	
		Chatterjee, B., <i>et al.</i> , "BMP regulation of the mouse connexin43 promoter in osteoblastic cells and embryos," <i>Cell Communication and Adhesion</i> 10:37-50 (2003).	
		Contag, <i>et al.</i> , "Advances in <i>in vivo</i> bioluminescence imaging of gene expression," <i>Annual Review of Biomed. Eng.</i> 4:235-260 (2002).	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/570,117
				Filing Date	February 28, 2006
				First Named Inventor	Joerg Heyer
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket No.	GEN/022

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Coralli, C., <i>et al.</i> , "Limitations of the reporter green fluorescent protein under simulated tumor conditions," <i>Cancer Research</i> 61:4784-4790 (2001).	
		Elbashir <i>et al.</i> , "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> 26:199-213 (2002).	
		Giles <i>et al.</i> , "Caught up in a Wnt storm: Wnt signaling in cancer," <i>Biochimica et Biophysica Acta</i> 1653:1-24 (2003).	
		Hannon, "RNA interference," <i>Nature</i> 418:244-251 (2002).	
		Jacks <i>et al.</i> , "Effects of an Rb mutation in the mouse," <i>Nature</i> 359:295-300 (1992).	
		Kim <i>et al.</i> , "Survivin and molecular pathogenesis of colorectal cancer," <i>Lancet</i> 362:205-209 (2003).	
		Massuda, E.S., <i>et al.</i> , "Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells," <i>Proc. Nat'l. Acad. Sci.</i> 94:14701-14706 (1997).	
		McManus, M.T., <i>et al.</i> , "Gene silencing in mammals by small interfering RNAs," <i>Nature Reviews</i> 3:737-747 (2002).	
		Staal, F.J.T., <i>et al.</i> , "Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells," <i>Int'l Immunology</i> 11:317-323 (1999).	
		Vooijs <i>et al.</i> , "Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice," <i>Cancer Res.</i> 62(6):1862-1867 (2002).	
		Young, M.R. <i>et al.</i> , "Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion," <i>Proc. Natl. Acad. Sci.</i> 96:9827-9832 (1999).	
		Zhong, S., <i>et al.</i> , "Organ-specific activation of acitvator protein-1 in transgenic mice by 12-O-tetradecanoylphorbol-13-acetate with different administration methods," <i>Cancer Research</i> 61:4084-4091 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/570,117
				Filing Date	February 28, 2006
				First Named Inventor	Joerg Heyer
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket No.	GEN/022

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		Zhong, S.P., <i>et al.</i> , "Organ-specific distribution of AP-1 in AP-1 luciferase transgenic mice during the maturation process," <i>Am. J. Physiol Regul Integr Comp Physiol</i> 280:R376-R381 (2001).	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/570,117
				Filing Date	February 28, 2006
				First Named Inventor	Joerg Heyer
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket No.	GEN/022

U.S. PATENT DOCUMENTS					
Examiner initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4,736,866	04/12/88	Leder et al.	
		6,506,559	01/14/03	Fire et al.	
		6,639,121	10/28/03	DePinho et al.	
		2002/0086356	07/04/02	Tuschl et al.	

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 99/32619	07/01/99	The Carnegie Institute of Washington; The University of Massachusetts		
		WO 01/09308	02/08/01	Dana-Farber Cancer Institute		
		WO 01/36646	05/25/01	Cancer Research Campaign Technology Limited		
		WO 01/68836	09/20/01	Genetica, Inc.; Cold Spring Harbor Laboratory		

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Bao, R., et al., "Activation of cancer-specific gene expression by the survivin promoter," <i>J. of the National Cancer Inst.</i> 94:522-528 (2002).	
		Chatterjee, B., et al., "BMP regulation of the mouse connexin43 promoter in osteoblastic cells and embryos," <i>Cell Communication and Adhesion</i> 10:37-50 (2003).	
		Contag, et al., "Advances in <i>in vivo</i> bioluminescence imaging of gene expression," <i>Annual Review of Biomed. Eng.</i> 4:235-260 (2002).	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460.

Substitute for form 1449A/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/570,117
				Filing Date	February 28, 2006
				First Named Inventor	Joerg Heyer
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
(use as many sheets as necessary)				Attorney Docket No.	GEN/022
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Coralli, C., <i>et al.</i> , "Limitations of the reporter green fluorescent protein under simulated tumor conditions," <i>Cancer Research</i> 61:4784-4790 (2001).	
		Elbashir <i>et al.</i> , "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> 26:199-213 (2002).	
		Giles <i>et al.</i> , "Caught up in a Wnt storm: Wnt signaling in cancer," <i>Biochimica et Biophysica Acta</i> 1653:1-24 (2003).	
		Hannon, "RNA interference," <i>Nature</i> 418:244-251 (2002).	
		Jacks <i>et al.</i> , "Effects of an Rb mutation in the mouse," <i>Nature</i> 359:295-300 (1992).	
		Kim <i>et al.</i> , "Survivin and molecular pathogenesis of colorectal cancer," <i>Lancet</i> 362:205-209 (2003).	
		Massuda, E.S., <i>et al.</i> , "Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells," <i>Proc. Nat'l. Acad. Sci.</i> 94:14701-14706 (1997).	
		McManus, M.T., <i>et al.</i> , "Gene silencing in mammals by small interfering RNAs," <i>Nature Reviews</i> 3:737-747 (2002).	
		Staal, F.J.T., <i>et al.</i> , "Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells," <i>Int'l Immunology</i> 11:317-323 (1999).	
		Vooijs <i>et al.</i> , "Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice," <i>Cancer Res.</i> 62(6):1862-1867 (2002).	
		Young, M.R. <i>et al.</i> , "Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion," <i>Proc. Natl. Acad. Sci.</i> 96:9827-9832 (1999).	
		Zhong, S., <i>et al.</i> , "Organ-specific activation of acitvator protein-1 in transgenic mice by 12-O-tetradecanoylphorbol-13-acetate with different administration methods," <i>Cancer Research</i> 61:4084-4091 (2001).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/570,117
				Filing Date	February 28, 2006
				First Named Inventor	Joerg Heyer
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket No.	GEN/022

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Zhong, S.P., <i>et al.</i> , "Organ-specific distribution of AP-1 in AP-1 luciferase transgenic mice during the maturation process," <i>Am. J. Physiol Regul Integr Comp Physiol</i> 280:R376-R381 (2001).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.